Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — Intellectual property legal development expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:IntellectualPropertyLegalDevelopmentExpenses.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Gross profit | 207,229 | 101,030 | 26,249 | — | 334,508 |
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — intellectual property legal development expenses?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — intellectual property legal development expenses of $0 in Q2 2026.
- What does avkare — intellectual property legal development expenses mean?
- Reflects costs associated with protecting, maintaining, and defending the intellectual property rights of the AvKARE segment's product portfolio. These expenses are critical for sustaining competitive advantages and preventing market entry by generic or biosimilar competitors.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — intellectual property legal development expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude